Back to List View Graph View

Rituximab

Rituximab is a chimeric monoclonal antibody used as a therapeutic agent that depletes B lymphocytes.

Where the papers sit

35 papers from the last 6 months study rituximab directly · updated from PubMed 16 Nov 2026

  • Rituximab in Autoimmunity

    Real-world rituximab use is expanding across myasthenia gravis, immune thrombocytopenia, interstitial lung disease and membranous nephropathy. Studies are testing low-dose treatment, combination with thrombopoietin receptor agonists and varied retreatment protocols against clinical improvement and remission. Baseline immunoglobulin testing and pharmacovigilance are gaining emphasis because hypogammaglobulinemia and adverse events constrain repeated B-cell depletion. Proteinuria selectivity and acetylcholine receptor status illustrate the push toward disease-specific response prediction.

    9 papers · 25.7%

  • B-Cell Lymphoma Therapy

    Combination regimens are moving beyond rituximab alone in relapsed and untreated B-cell malignancies. Follicular lymphoma studies pair it with lenalidomide and epcoritamab, assessing progression-free survival, remission and neutropenia. Maintenance remains important, while transformed disease and rare EBV-positive lymphoproliferation highlight longer-term risks. Ibrutinib- and vemurafenib-containing approaches extend this treatment strategy to mantle cell lymphoma and hairy cell leukemia.

    7 papers · 20%

  • B-Cell Depletion in Lupus Nephritis

    B-cell depletion is being evaluated as a durable strategy for refractory and severe lupus nephritis, with attention to renal remission and glomerular filtration. Longitudinal studies track lymphocyte reconstitution and immunophenotypic changes over years of sustained remission. Comparisons with mycophenolate mofetil and cyclophosphamide are defining where rituximab-based treatment fits in standard care. Renal biopsy findings and antibody profiles remain important for predicting response and relapse.

    4 papers · 11.4%

  • Others — Anti-CD20 Neuroimmunology

    Anti-CD20 treatment is being optimized across multiple sclerosis through comparisons with ocrelizumab, extended dosing intervals and management around pregnancy. Disease activity, treatment response and late-onset neutropenia remain central clinical endpoints. Related work examines rituximab in NMOSD, MOGAD and anti-MAG neuropathy, while antibody-receptor architecture studies address biological determinants of binding. The cluster therefore combines a strong MS focus with broader and partly unrelated neuroimmunology research.

    10 papers · 28.6%

  • Others — Cross-Disease Rituximab Evidence

    The group combines treatment comparisons in chronic lymphocytic leukemia, systemic sclerosis and minimal change disease with pharmacokinetic and economic analyses. Zanubrutinib is tested against fludarabine, cyclophosphamide and rituximab, while other studies compare intensive immunosuppression or glucocorticoid strategies with standard care. Population pharmacokinetics and biosimilar costing address how rituximab is delivered rather than one shared disease mechanism. No single clinical direction unites these papers beyond evaluating treatment choice, exposure or value.

    5 papers · 14.3%

PARADIGM SHIFT

Rituximab can move from rescue therapy to an early, steroid-sparing treatment strategy

The adult newly diagnosed minimal change disease cohort and the early-treatment AChR-positive generalized myasthenia gravis cohort both challenge the assumption that rituximab is chiefly a treatment for refractory disease after standard glucocorticoid therapy has failed. In minimal change disease, rituximab combined with low-dose, short-course glucocorticoids produced remission rates comparable to standard full-dose glucocorticoids, with fewer relapses and markedly less glucocorticoid toxicity 42979794Nov; in previously untreated generalized myasthenia gravis, a single low dose of rituximab was followed by rapid clinical improvement and substantial steroid reduction 42419026Jul. Together, these findings support testing rituximab earlier and at lower intensity to reduce exposure to conventional glucocorticoids rather than reserving it for treatment-resistant disease.

NEW DIRECTION

Rituximab is being used preemptively to widen the safety margin of checkpoint blockade

The randomized-trial analysis of rituximab-mediated B-cell depletion in patients receiving combined CTLA-4/PD-1 blockade for advanced melanoma assigns rituximab a role distinct from its other uses in the set: preventing or mitigating checkpoint-induced immune toxicity while preserving antitumor activity, rather than treating the cancer or an established autoimmune disease 42969237Nov. Despite early trial discontinuation because of rituximab hypersensitivity, preemptive depletion was associated with fewer severe toxicities without evident loss of antitumor effect, creating a potential immune-reset strategy for separating checkpoint efficacy from immune-related adverse events.

Papers

The 35 papers from the last 6 months that study rituximab directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Rituximab in Autoimmunity (9)
  1. B cells and the therapeutic index of checkpoint blockade. The Journal of clinical investigation · 2 Nov 2026 PMID 42969237
  2. Pre-Rituximab Immunoglobulin Testing and Baseline Hypogammaglobulinemia Across Rituximab Indications in Adults: A Multisite Retrospective Study. The journal of allergy and clinical immunology. In practice · 30 Oct 2026 PMID 42962919
  3. Combination of Thrombopoietin Receptor Agonists and Rituximab in Relapsed/Refractory Immune Thrombocytopenia: A Multicenter Real-World Study. Journal of thrombosis and haemostasis : JTH · 26 Oct 2026 PMID 42933655
  4. Real-world pharmacovigilance of rituximab-associated adverse reactions in children and adolescents: Disproportionality signal detection and time-to-onset pattern characterization using the FAERS database. Human vaccines & immunotherapeutics · 29 Sept 2026 PMID 42808785
  5. Idiopathic fibrosing mediastinitis mimicking malignancy: when imaging deceives. BMJ case reports · 24 Aug 2026 PMID 42637505
  6. Rituximab in progressive connective tissue disease-associated interstitial lung disease: A multicenter real-world cohort study. Respiratory medicine · 13 Aug 2026 PMID 42595268
  7. Proteinuria selectivity index as a predictor of remission and rituximab efficacy in primary membranous nephropathy: a single-center retrospective analysis. Renal failure · 31 Jul 2026 PMID 42535733
  8. Rituximab in AChR and MusK Myasthenia Gravis: long-term follow-up with different therapeutic protocols. Journal of the neurological sciences · 23 Jul 2026 PMID 42492144
  9. Early use of low dose rituximab in anti acetylcholine receptor generalized myasthenia gravis in South Wales - A retrospective study. Journal of the neurological sciences · 8 Jul 2026 PMID 42419026
B-Cell Lymphoma Therapy (7)
  1. Patterns of care, outcomes, and prognostics for transformed follicular lymphoma in the rituximab era. Haematologica · 24 Sept 2026 PMID 42779337
  2. Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial. The Lancet. Haematology · 27 Aug 2026 PMID 42660129
  3. Acute development of EBV+ T-cell lymphoproliferative disorder after treatment with rituximab for follicular lymphoma. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 25 Aug 2026 PMID 42641986
  4. Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 14 Jul 2026 PMID 42447409
  5. Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma. Oncoimmunology · 8 Jul 2026 PMID 42415230
  6. RENOIR phase 3 rituximab-lenalidomide vs rituximab as maintenance treatment in relapsed/refractory follicular lymphoma. Blood advances · 25 Jun 2026 PMID 42349017
  7. Low-dose vemurafenib plus rituximab in frontline and relapsed or refractory hairy cell leukemia: the Scripps regimen. Blood advances · 17 Jun 2026 PMID 42308249
B-Cell Depletion in Lupus Nephritis (4)
  1. In Vivo Dynamics of Immunoregulatory Lymphocyte Reconstitution: A Seven-year Longitudinal Study of Sustained Remission in Class IV Lupus Nephritis Following Rituximab Therapy. In vivo (Athens, Greece) · 29 Oct 2026 PMID 42957221
  2. Clinical and immunological outcomes of rituximab-based, mycophenolate mofetil-based and cyclophosphamide-based treatment strategies for systemic lupus erythematosus with active kidney involvement from LOOPS registry. RMD open · 25 Sept 2026 PMID 42791028
  3. Déjà vu. BMJ case reports · 16 Sept 2026 PMID 42749346
  4. Longitudinal Immunophenotypic Changes in Refractory Lupus Nephritis After B-cell Depletion: A 25-year Case Study. In vivo (Athens, Greece) · 28 Aug 2026 PMID 42665415
Others — Anti-CD20 Neuroimmunology (10)
  1. Long-term outcomes and predictors of response to rituximab in anti-MAG neuropathy: a multicenter real-world study. Journal of neurology · 5 Nov 2026 PMID 42986466
  2. ABCD-Trial: study protocol for a randomized, double-blind, placebo-controlled study in patients with Amyotrophic lateral sclerosis for the evaluation of efficacy and safety of B-Cell Depletion with rituximab (ABCD). Trials · 21 Oct 2026 PMID 42902402
  3. Clinical phenotype and treatment response in AQP4-IgG-positive NMOSD and MOGAD: insights from the Italian I-MS&RD registry. Journal of neurology · 15 Oct 2026 PMID 42881253
  4. Disease Activity During Pregnancy and Postpartum in Women With Multiple Sclerosis Treated With Ocrelizumab or Rituximab Before Pregnancy. Neurology(R) neuroimmunology & neuroinflammation · 9 Oct 2026 PMID 42854176
  5. Late-Onset Neutropenia After Rituximab in Multiple Sclerosis: Incidence, Predictors, and Outcomes in a Retrospective Multicenter Cohort. Neurology(R) neuroimmunology & neuroinflammation · 15 Sept 2026 PMID 42743451
  6. Optimizing rituximab dosing in multiple sclerosis: Real-world outcomes with interval extension. Multiple sclerosis and related disorders · 12 Sept 2026 PMID 42731333
  7. Expansion Microscopy Reveals the Spatial Association of Therapeutic Antibody-Receptor Complexes With Cholesterol-Rich Membrane Domains. Angewandte Chemie (International ed. in English) · 25 Aug 2026 PMID 42638193
  8. Child Neurology: A Case of Concurrent Neurofibromatosis Type 1 and Multiple Sclerosis by 2024 Criteria. Neurology · 22 Jul 2026 PMID 42485588
  9. Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis. The New England journal of medicine · 1 Jul 2026 PMID 42384870
  10. Impact of Clustered Antigenic Architectures on the Adhesion of Monoclonal Antibodies: Insights from Biomimetic Model Surfaces. Analytical chemistry · 22 Jun 2026 PMID 42331022
Others — Cross-Disease Rituximab Evidence (5)
  1. Rituximab combined with low-dose, short-course glucocorticoids versus standard glucocorticoid therapy in adults with newly diagnosed minimal change disease: A retrospective cohort study. Nephrologie & therapeutique · 4 Nov 2026 PMID 42979794
  2. Uncovering the full economic impact of biosimilars: a "would have spent" counterfactual analysis of five reference biologics (infliximab, adalimumab, bevacizumab, rituximab, and trastuzumab) in the United States and Europe, 2016-2025. Journal of medical economics · 28 Oct 2026 PMID 42948929
  3. Zanubrutinib versus fludarabine, cyclophosphamide and rituximab in fit, treatment-naïve patients with chronic lymphocytic leukemia: a matching-adjusted indirect comparison. Journal of comparative effectiveness research · 21 Aug 2026 PMID 42626928
  4. Population Pharmacokinetics of Rituximab in Treatment-Naïve Chinese Patients With Diffuse Large B-cell Lymphoma During Induction Therapy: Clinical Implications. Clinical and translational science · 25 Jul 2026 PMID 42499290
  5. High-intensity immunosuppression versus modern standard care in poor-prognosis diffuse cutaneous systemic sclerosis: A propensity-matched study. Journal of autoimmunity · 26 Jun 2026 PMID 42361515

By study type

Clinical trials (6)
  1. ABCD-Trial: study protocol for a randomized, double-blind, placebo-controlled study in patients with Amyotrophic lateral sclerosis for the evaluation of efficacy and safety of B-Cell Depletion with rituximab (ABCD). Trials · 21 Oct 2026 PMID 42902402
  2. Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial. The Lancet. Haematology · 27 Aug 2026 PMID 42660129
  3. Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 14 Jul 2026 PMID 42447409
  4. Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma. Oncoimmunology · 8 Jul 2026 PMID 42415230
  5. Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis. The New England journal of medicine · 1 Jul 2026 PMID 42384870
  6. RENOIR phase 3 rituximab-lenalidomide vs rituximab as maintenance treatment in relapsed/refractory follicular lymphoma. Blood advances · 25 Jun 2026 PMID 42349017
Observational studies and case reports (20)
  1. Long-term outcomes and predictors of response to rituximab in anti-MAG neuropathy: a multicenter real-world study. Journal of neurology · 5 Nov 2026 PMID 42986466
  2. Rituximab combined with low-dose, short-course glucocorticoids versus standard glucocorticoid therapy in adults with newly diagnosed minimal change disease: A retrospective cohort study. Nephrologie & therapeutique · 4 Nov 2026 PMID 42979794
  3. In Vivo Dynamics of Immunoregulatory Lymphocyte Reconstitution: A Seven-year Longitudinal Study of Sustained Remission in Class IV Lupus Nephritis Following Rituximab Therapy. In vivo (Athens, Greece) · 29 Oct 2026 PMID 42957221
  4. Clinical phenotype and treatment response in AQP4-IgG-positive NMOSD and MOGAD: insights from the Italian I-MS&RD registry. Journal of neurology · 15 Oct 2026 PMID 42881253
  5. Disease Activity During Pregnancy and Postpartum in Women With Multiple Sclerosis Treated With Ocrelizumab or Rituximab Before Pregnancy. Neurology(R) neuroimmunology & neuroinflammation · 9 Oct 2026 PMID 42854176
  6. Clinical and immunological outcomes of rituximab-based, mycophenolate mofetil-based and cyclophosphamide-based treatment strategies for systemic lupus erythematosus with active kidney involvement from LOOPS registry. RMD open · 25 Sept 2026 PMID 42791028
  7. Déjà vu. BMJ case reports · 16 Sept 2026 PMID 42749346
  8. Late-Onset Neutropenia After Rituximab in Multiple Sclerosis: Incidence, Predictors, and Outcomes in a Retrospective Multicenter Cohort. Neurology(R) neuroimmunology & neuroinflammation · 15 Sept 2026 PMID 42743451
  9. Optimizing rituximab dosing in multiple sclerosis: Real-world outcomes with interval extension. Multiple sclerosis and related disorders · 12 Sept 2026 PMID 42731333
  10. Longitudinal Immunophenotypic Changes in Refractory Lupus Nephritis After B-cell Depletion: A 25-year Case Study. In vivo (Athens, Greece) · 28 Aug 2026 PMID 42665415
  11. Acute development of EBV+ T-cell lymphoproliferative disorder after treatment with rituximab for follicular lymphoma. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 25 Aug 2026 PMID 42641986
  12. Idiopathic fibrosing mediastinitis mimicking malignancy: when imaging deceives. BMJ case reports · 24 Aug 2026 PMID 42637505
  13. Rituximab in progressive connective tissue disease-associated interstitial lung disease: A multicenter real-world cohort study. Respiratory medicine · 13 Aug 2026 PMID 42595268
  14. Proteinuria selectivity index as a predictor of remission and rituximab efficacy in primary membranous nephropathy: a single-center retrospective analysis. Renal failure · 31 Jul 2026 PMID 42535733
  15. Population Pharmacokinetics of Rituximab in Treatment-Naïve Chinese Patients With Diffuse Large B-cell Lymphoma During Induction Therapy: Clinical Implications. Clinical and translational science · 25 Jul 2026 PMID 42499290
  16. Rituximab in AChR and MusK Myasthenia Gravis: long-term follow-up with different therapeutic protocols. Journal of the neurological sciences · 23 Jul 2026 PMID 42492144
  17. Child Neurology: A Case of Concurrent Neurofibromatosis Type 1 and Multiple Sclerosis by 2024 Criteria. Neurology · 22 Jul 2026 PMID 42485588
  18. Early use of low dose rituximab in anti acetylcholine receptor generalized myasthenia gravis in South Wales - A retrospective study. Journal of the neurological sciences · 8 Jul 2026 PMID 42419026
  19. High-intensity immunosuppression versus modern standard care in poor-prognosis diffuse cutaneous systemic sclerosis: A propensity-matched study. Journal of autoimmunity · 26 Jun 2026 PMID 42361515
  20. Low-dose vemurafenib plus rituximab in frontline and relapsed or refractory hairy cell leukemia: the Scripps regimen. Blood advances · 17 Jun 2026 PMID 42308249
Human data, design not indexed (4)
  1. Uncovering the full economic impact of biosimilars: a "would have spent" counterfactual analysis of five reference biologics (infliximab, adalimumab, bevacizumab, rituximab, and trastuzumab) in the United States and Europe, 2016-2025. Journal of medical economics · 28 Oct 2026 PMID 42948929
  2. Real-world pharmacovigilance of rituximab-associated adverse reactions in children and adolescents: Disproportionality signal detection and time-to-onset pattern characterization using the FAERS database. Human vaccines & immunotherapeutics · 29 Sept 2026 PMID 42808785
  3. Zanubrutinib versus fludarabine, cyclophosphamide and rituximab in fit, treatment-naïve patients with chronic lymphocytic leukemia: a matching-adjusted indirect comparison. Journal of comparative effectiveness research · 21 Aug 2026 PMID 42626928
  4. Impact of Clustered Antigenic Architectures on the Adhesion of Monoclonal Antibodies: Insights from Biomimetic Model Surfaces. Analytical chemistry · 22 Jun 2026 PMID 42331022
Preclinical: animal, cell and lab studies (2)
  1. B cells and the therapeutic index of checkpoint blockade. The Journal of clinical investigation · 2 Nov 2026 PMID 42969237
  2. Expansion Microscopy Reveals the Spatial Association of Therapeutic Antibody-Receptor Complexes With Cholesterol-Rich Membrane Domains. Angewandte Chemie (International ed. in English) · 25 Aug 2026 PMID 42638193
Unclassified: not yet indexed with MeSH (3)
  1. Pre-Rituximab Immunoglobulin Testing and Baseline Hypogammaglobulinemia Across Rituximab Indications in Adults: A Multisite Retrospective Study. The journal of allergy and clinical immunology. In practice · 30 Oct 2026 PMID 42962919
  2. Combination of Thrombopoietin Receptor Agonists and Rituximab in Relapsed/Refractory Immune Thrombocytopenia: A Multicenter Real-World Study. Journal of thrombosis and haemostasis : JTH · 26 Oct 2026 PMID 42933655
  3. Patterns of care, outcomes, and prognostics for transformed follicular lymphoma in the rituximab era. Haematologica · 24 Sept 2026 PMID 42779337